Matthia Brendel, MD, is group leader in molecular imaging of neurodegenerative diseases of the Department of Nuclear Medicine at the Ludwig-Maximilians Universität München. His principal research focus is in translational molecular neuroimaging by PET in neurodegenerative disorders, aiming to disentangle associations between protein aggregation and neuroinflammation. As PI and co-Investigator on several university-funded grants, Brendel successfully administered projects, collaborated with multiple researchers and produced several peer-reviewed publications from each project. Since his doctoral thesis, Brendel published several preclinical studies and of one, the first methodological evaluations of amyloid PET in dedicated small models that focused on validation and establishment of novel PET tracer in the field. Moreover, he has a proven track record for coordinating academic research studies including a recent multi-center study on second generation tau-PET in progressive supranuclear palsy.